TopDollar Investing

[UndergroundTrader]

OCLG Report:

http://www.oclghealth.com/

Headquarters - New Orleans, LA
Administrative Office - Grand Rapids, MI
Amian Angels - Lafayette/Alexandria, LA
Advanced Medical Products & Technologies - Phoenix, AZ
Dotolo Reasearch Corporation - Phoenix, AZ
Esteemcare - Columbia, SC

Our primary mission is to acquire and grow profitable operations that build, maintain and nourish stakeholder value.

Our business model combines certain relationships between medical device products, healthcare services, home medical product sales and product distribution that provide related products, health services, new markets and opportunities.

The combined sales, marketing, and operational synergies will enable our business units to provide a wide variety of complete technology solutions at significant cost savings.

The OCLG management team possesses the operational and financial skills required to effectively implement its sales, marketing and operational strategy, and successfully realize the company’s growth and profitability projections.

We strive to continuously acquire businesses that offer products, services, and technologies which optimize human life with mobility issues, pain management, functional problems, assistance with activities of daily living, etc.

Subsidiaries:

Advanced Medical Products & Technologies
EsteemCare
Amian Angels

Markets: http://www.oclghealth.com/about-us/key-industries

A/S - 750,000,000
Last known O/S - 340,126,946

We've seen trading in approx .0003 - .0007 range since Sept 2014.

They are currently a Pink Yield.

Last Q was for the period ending 5/31/2015, with fiscal year ending 8/31/2015 http://www.otcmarkets.com/edgar/GetFilingHtmlFilingID=10854460

The 10-K is late, hence the yield.

The Q shows growing assets and revs, but growing debts as well, with debts exceeding assets. Most of the debts being toxic. Very troubling for the company, however, revs are up 35% over same period last year totaling $3,625,407 for 9 months.

It almost seems contrary to their mission of limiting bad debt, but the growth they tout seems to be occurring. The mission did just appear as the website was launched: Oct 20, 2015 http://www.irdirect.net/pr/release/id/1555569


They had issued a PR concerning their last Q results: July 21, 2015

http://www.irdirect.net/pr/release/id/1406434

Wayne Erwin, CEO of Oncologix, stated, "We are very pleased with the results of our third quarter fiscal 2015. We increased our division sales revenues by organic growth and we will continue to focus on debt reduction over the next three (3) months."

This was concerning given in July the stock was at .002, and 3 months later, it was at .0003. The flood gates obviously had too many holes to plug, even with efforts to plug them. They have been claiming to have been trying:

"it is our primary intent to pay off these debt instruments prior to them becoming due whenever possible."

"we are confident that our stock values will rise from its current, low levels. The Enterprise Values of the Company remains evident."

- Retired over $170,000 in convertible note debts between October 2014 thru May 2015, from operating capital preventing 65 million shares from being sold into the market.

That $170k really was a drop in the bucket though.

The real question remains, how much have they paid off from May 2015 to Feb, 2016.

One thing we do know - the O/S, as of Feb 10, 2015 remains at 750,000,000 according to NV SOS - http://nvsos.gov/sosentitysearch/CorpDetails.aspx?lx8nvq=UwGmau%252fMI39WMM1VDsGvfQ%253d%253d&nt7=0

At the current level of .0003, even at a maxed A/S, which is just for show, since I am not sure at this time, the market cap remains at $225,000. The historical low is .0002, and has never hit .0001

More investigation to be done, but the story is compelling enough for me to start a position at .0003, and a bid at .0002. Questions and Comments Welcome.